Cardiovascular disease in women with breast cancer - a nationwide cohort study.
Adult
Aged
Aged, 80 and over
Breast Neoplasms
/ diagnosis
Cardiovascular Diseases
/ epidemiology
Case-Control Studies
Cohort Studies
Comorbidity
Denmark
/ epidemiology
Female
Heart Failure
/ epidemiology
Humans
Incidence
Middle Aged
Prevalence
Pulmonary Embolism
/ epidemiology
Pulmonary Heart Disease
/ epidemiology
Registries
Thrombophlebitis
/ epidemiology
Thrombosis
/ epidemiology
Time Factors
Breast cancer
Cardiovascular disease
Cohort study
Incidence
Matched control group
Prevalence
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
18 Sep 2021
18 Sep 2021
Historique:
received:
11
11
2020
accepted:
23
08
2021
entrez:
19
9
2021
pubmed:
20
9
2021
medline:
21
10
2021
Statut:
epublish
Résumé
There is increasing concern about cardiovascular disease (CVD) after breast cancer (BC). The aim of this study was to estimate the prevalence of different types of CVD in women diagnosed with BC compared to cancer-free controls as well as the incidence of CVD after BC diagnosis. We performed a cohort study based on data from national registries covering the entire Danish population. We followed 16,505 cancer-naïve BC patients diagnosed from 2003 to 2007 5 years before and up to 10 years after BC diagnosis compared to 165,042 cancer-free controls. We found that 15.6% of BC patients were registered with at least one CVD diagnosis in hospital records before BC diagnosis. Overall, BC patients and controls were similar with regard to CVD comorbidity before BC diagnosis. After BC diagnosis, the incidence of all CVD diagnoses combined was significantly higher in BC patients than controls up to approximately 6 years after the index date (BC diagnosis). After 10 years, 28% of both BC patients and controls (without any CVD diagnosis up to 5 years before the index date) had at least one CVD diagnosis according to hospital records. However, the incidence of heart failure, thrombophlebitis/thrombosis and pulmonary heart disease including pulmonary embolism remained higher in BC patients than controls during the entire 10-year follow-up period. After 10 years, 2.7% of BC patients compared to 2.5% of controls were diagnosed with heart failure, 2.7% of BC patients compared to 1.5% of controls were diagnosed with thrombophlebitis/thrombosis, and 1.5% of BC patients compared to 1.0% of controls were diagnosed with pulmonary heart disease according to hospital records. Furthermore, we found that the risk of heart failure and thrombophlebitis/thrombosis was higher after chemotherapy. Focus on CVD in BC patients is important to ensure optimum treatment with regard to BC as well as possible CVD. Strategies to minimise and manage the increased risk of heart failure, thrombophlebitis/thrombosis and pulmonary heart disease including pulmonary embolism in BC patients are especially important.
Sections du résumé
BACKGROUND
BACKGROUND
There is increasing concern about cardiovascular disease (CVD) after breast cancer (BC). The aim of this study was to estimate the prevalence of different types of CVD in women diagnosed with BC compared to cancer-free controls as well as the incidence of CVD after BC diagnosis.
METHODS
METHODS
We performed a cohort study based on data from national registries covering the entire Danish population. We followed 16,505 cancer-naïve BC patients diagnosed from 2003 to 2007 5 years before and up to 10 years after BC diagnosis compared to 165,042 cancer-free controls.
RESULTS
RESULTS
We found that 15.6% of BC patients were registered with at least one CVD diagnosis in hospital records before BC diagnosis. Overall, BC patients and controls were similar with regard to CVD comorbidity before BC diagnosis. After BC diagnosis, the incidence of all CVD diagnoses combined was significantly higher in BC patients than controls up to approximately 6 years after the index date (BC diagnosis). After 10 years, 28% of both BC patients and controls (without any CVD diagnosis up to 5 years before the index date) had at least one CVD diagnosis according to hospital records. However, the incidence of heart failure, thrombophlebitis/thrombosis and pulmonary heart disease including pulmonary embolism remained higher in BC patients than controls during the entire 10-year follow-up period. After 10 years, 2.7% of BC patients compared to 2.5% of controls were diagnosed with heart failure, 2.7% of BC patients compared to 1.5% of controls were diagnosed with thrombophlebitis/thrombosis, and 1.5% of BC patients compared to 1.0% of controls were diagnosed with pulmonary heart disease according to hospital records. Furthermore, we found that the risk of heart failure and thrombophlebitis/thrombosis was higher after chemotherapy.
CONCLUSIONS
CONCLUSIONS
Focus on CVD in BC patients is important to ensure optimum treatment with regard to BC as well as possible CVD. Strategies to minimise and manage the increased risk of heart failure, thrombophlebitis/thrombosis and pulmonary heart disease including pulmonary embolism in BC patients are especially important.
Identifiants
pubmed: 34537007
doi: 10.1186/s12885-021-08716-5
pii: 10.1186/s12885-021-08716-5
pmc: PMC8449438
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1040Subventions
Organisme : Pfizer Denmark
ID : Not applicable
Informations de copyright
© 2021. The Author(s).
Références
Radiother Oncol. 2017 May;123(2):299-305
pubmed: 28365142
Acta Oncol. 2018 Jan;57(1):129-134
pubmed: 29202645
Int J Epidemiol. 2017 Jun 1;46(3):798-798f
pubmed: 27789670
Br J Cancer. 2012 Mar 27;106(7):1353-60
pubmed: 22353805
Scand J Public Health. 2011 Jul;39(7 Suppl):42-5
pubmed: 21775350
J Natl Cancer Inst. 2019 Aug 1;111(8):854-862
pubmed: 30715404
BMJ. 1992 Jul 25;305(6847):225-6
pubmed: 1392827
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Scand J Public Health. 2011 Jul;39(7 Suppl):22-5
pubmed: 21775345
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Breast Cancer Res Treat. 2012 Feb;131(3):1013-20
pubmed: 22002567
Breast Cancer Res Treat. 2012 Aug;135(1):281-9
pubmed: 22829398
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
J Clin Endocrinol Metab. 1995 Nov;80(11):3191-5
pubmed: 7593425
Clin Epidemiol. 2013 Nov 01;5(Suppl 1):3-29
pubmed: 24227920
BMJ. 2010 Mar 02;340:c845
pubmed: 20197326
J Clin Oncol. 1991 Feb;9(2):286-94
pubmed: 1988575
Eur J Heart Fail. 2008 Jul;10(7):658-60
pubmed: 18539522
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):241-9
pubmed: 17252614
Circulation. 2018 Feb 20;137(8):e30-e66
pubmed: 29437116
Scand J Public Health. 2011 Jul;39(7 Suppl):91-4
pubmed: 21775362
Breast. 2006 Jun;15(3):301-12
pubmed: 16230014
Clin Med Insights Oncol. 2014 Dec 04;8:129-37
pubmed: 25520567
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3
pubmed: 21775347
Circ Cardiovasc Qual Outcomes. 2018 Jul;11(7):e004580
pubmed: 29997149
Radiother Oncol. 2011 Aug;100(2):167-75
pubmed: 21752480
Scand J Public Health. 2011 Jul;39(7 Suppl):38-41
pubmed: 21775349
Lancet. 2019 Sep 21;394(10203):1041-1054
pubmed: 31443926